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Introduction 
Campylobacteriosis is the most common bacterial 
cause of gastrointestinal disease in humans, with chicken 
meat regarded as the most common source for human 
infection (Altekruse et al., 1999; Butzler, 2004; Kotula & 
Stern, 1984; Nauta et al., 2009; Skirrow, 1991). The 
disease frequently results in severe diarrhoea, while 
sequelae may include various forms of paralysis and 
potentially death e.g. reactive arthritis and Guillain–Barré 
syndrome (Nichols et al., 2012; Skirrow, 1977). Notably, 
incidence is primarily sporadic, with relatively few cases 
associated with outbreaks. 
There is a common acceptance that poultry meat 
products are the most common source of Campylobacter 
infection in humans with one species, C. jejuni, typically 
reported in 80-90% of cases, the balance being primarily 
C. coli with a range of other species being far less 
common (Altekruse et al., 1999). The current consensus 
and public health focus is predominantly towards 
reduction of Campylobacter-contamination in chicken 
products (Umaraw et al., 2017).  
This consensus view is supported by some very strong 
observational and experimental data. However, there 
remains a plethora of other sources and explanations for 
campylobacteriosis that make this consensus view 
problematic (Nelson & Harris, 2017).  Faecal 
contamination by animals and birds is widespread in soil, 
waterways, irrigated crops, etc as best evidenced by 
ubiquitous Escherichia coli isolation (Edberg et al., 2000).  
At present, advances in biotyping, especially molecular 
identification, are providing critical source/patient linkage 
information. However, this is simply one aspect of the 
historical competition between germ and miasma theories 
of disease (Loomis & Wing, 1990). Epidemiological 
studies need to embrace a wider, broader range of 
disciplines and views than just risk analysis  
(Susser, 1998). 
The concept of a 'miasma' viewpoint has been 
suggested to be unhelpful towards reducing the disease 
burden of campylobacteriosis (Wilson et al., 2006). 
However, if the single source concept is not producing 
sufficient results (Nelson & Harris, 2017), perhaps we 
should consider a broader scope of investigation.  
We reconsider campylobacteriosis epidemiology and 
attempt a rational alternative view to the current risk 
analysis focus. Specifically that campylobacteriosis 
sporadic incidence patterns arise primarily as a result of 
differences in individual immune susceptibility plus 
microbe exposure. 
 
Immune Susceptibility 
Relatively large proportions of any population exhibit 
or develop comparative immunodeficiencies and are 
therefore more vulnerable to diseases (Lund & O’Brien, 
2011). These are commonly the very young, elderly or 
otherwise immune-compromised individuals. Use of 
antibiotics appears also to increase susceptibility to 
infection, especially when used in the period 1 month to 2 
years prior to infection (Koningstein et al., 2011;  
Neal et al., 1996). 
Proton pump inhibitors have long been recognised to 
increase risk for campylobacteriosis (Bouwknegt et al., 
2014; Neal et al., 1996; Tam et al., 2009; Wei et al., 
2017). The slight increase in campylobacteriosis rates in 
the elderly is commonly thought to be associated with a 
natural age associated reduced stomach acidity, but 
evidence indicates this seldom occurs (Hurwitz et al., 
1997). Therefore other risk factors in this age group also 
need to be investigated. Differences in dietary fibre intake 
appears to affect the ability of Campylobacter to invade 
gut epithelium cells (Masanta et al., 2013), possibly 
through changing the concentration of short chain fatty 
acids (SCFA) derived from the gut microbiota. 
Campylobacter outbreak cases are much less common 
and typically involve a larger group of cases clustered via 
a common point source. This may be from specific food 
stuffs, such as liver (Edwards et al., 2014), commercial 
catering (Mazick et al., 2006; Osimani & Clementi, 2016), 
dairy products (Taylor et al., 2013) and contaminated 
water sources (Gallay et al., 2006; Kuusi et al., 2004). 
Therefore outbreaks probably represent increased 
opportunity for infection by providing an infectious dose 
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sufficiently large to overwhelm innate and/or adaptive 
protective mechanisms of most people. 
Susceptibility to infection in a campylobacteriosis 
context can therefore relate to one or more specific 
changes. These include: 
 reduced immune response to infection induced by 
disease, pathogen or medication associated 
immunodeficiencies 
 prior use of antibiotics 
 changes in natural barriers to infection such as proton 
pump inhibitor medication  
 opportunity for infection as clearly evidenced in 
outbreak case clusters, i.e. overwhelming infectious 
dose or novel strains. 
 
Immunity 
An innate immune reaction to Campylobacter 
infections has been suggested previously. For example 
“individual susceptibility” (Rodrigues et al., 2000), 
“previous exposure may confer protection against 
subsequent infection” (Forbes et al., 2009), and 
“population immunity” (Nichols et al., 2012). 
Development of such immune reactions is already 
exploited in animal health (Sahin et al., 2017) against 
Campylobacter in ovine (Fenwick et al., 2000) and bovine 
(Hoffer, 1981) farming using commercially available 
vaccines, suggesting an opportunity for human protection 
too (Scott, 1997; Tribble et al., 2010). An equivalent 
vaccination for chickens, while receiving considerable 
investment, has failed to prove as effective (De Zoete et 
al., 2007; Meunier et al., 2016).  
Specific immune responses in humans to 
Campylobacter infection have been reported (Baqar et al., 
2001; Cawthraw et al., 2002). Surveys indicate an 
apparent immunity associated with prior and continued 
exposure, for example through occupational exposure 
(Cawthraw et al., 2000; De Perio et al., 2013; Ellström et 
al., 2014; Vegosen et al., 2015; Wilson, 2004), including 
dose-response development of immunity markers. Sero-
epidemiological surveys indicate very high exposure to 
Campylobacter infection by early adulthood within 
European populations (Ang et al., 2007; Ang et al., 2011; 
Teunis et al., 2013). However, any immunity from prior 
exposure appears to be strain specific (Kirkpatrick et al., 
2013), is dose related and degrades fairly rapidly (Tribble 
et al., 2010). 
Within developing countries, immunity markers are 
prevalent in older populations without associated 
diarrhoea symptoms (Coker et al., 2002; Havelaar et al., 
2009). This effect is presumably associated with 
continued exposure and maintenance boosting of 
immunity, similar to that reported through occupational 
exposure in developed countries. 
 
Discussion 
Humans are exposed to a very wide range of species 
and biotypes of Campylobacter, from very broadly 
defined sources and via mechanisms clearly far wider than 
food contamination (Nelson & Harris, 2017). Within this 
exposure pattern, individuals also vary in susceptibility.  
A broader discussion beyond simply controlling 
Campylobacter contamination in specific food sources is 
required in order to tackle combating campylobacteriosis. 
Recognition of the presence of an immune response 
reaction in humans indicates the potential for some sort of 
prophylactic immune-system priming. Development of 
killed whole-cell vaccine for oral treatment has shown 
promise in animal models (Baqar et al., 1995), but 
vaccines for human use remain problematic (Jagusztyn-
Krynicka et al., 2009). Whole-cell killed vaccines have 
shown particular promise against other diseases, 
especially where there is endemicity and an environmental 
exposure, such as those against Cholera (Kirpich et al., 
2017) or Helicobacter pylori (both vibrios and so close 
relatives of Campylobacter) (Summerton et al., 2010). 
In some respects, properly cooked (Campylobacter) 
contaminated foodstuffs could in fact prove to have the 
same whole-cell killed vaccine effect (Tam et al., 2009), 
thus explaining the source of frequent exposure without 
illness as evidenced by sero-epidemiology studies (Teunis 
et al., 2013). Thus, in a counter intuitive manner, the 
current efforts to eradicate Campylobacter from chicken 
products may in fact prove counterproductive in some 
respects by reducing the frequency of our ongoing 
exposure and immune priming to the bacteria. This prior 
immune priming may provide some protection against 
larger infectious dose cases, including outbreaks, but still 
largely does not explain the much larger proportion of 
sporadic cases.  
The benefit of killed whole-cell vaccines is that a broad 
range of biotypes, typical of the specific region targeted 
for protection, can probably be developed relatively 
quickly and cheaply. Medication via a common food, such 
as a milk drink or freeze-dried formulation for oral 
dosage, might prove one means of establishing 
population-level immunity. In particular, increased risk 
immuno-compromised groups might obtain particular 
benefit from such protective treatment.  The relatively 
high incidence of campylobacteriosis in travellers could 
similarly be addressed by oral dosage of locally prepared 
‘medicated’ food or drink when travelling.  Eating 
properly cooked local produce could also be expected to 
provide more immunity to more commonly encountered 
local environmental strains. Interestingly, this approach 
would support the ‘Slow Food’ movement 
which encourages farming of plants, seeds, and livestock 
characteristic of the local ecosystem. 
The two most common environmental species of 
Campylobacter, C. jejuni and C. coli (Jones et al., 2017) 
are the most likely to infect local chicken production 
facilities. This presumably then means regular 
consumption of properly cooked chicken foods derived 
from infected chickens has quite possibly been acting as a 
natural killed whole-cell vaccine for the human population 
also exposed to the same environmental Campylobacter 
strains. Broad strain variation load and early colonisation 
is common in free-range flocks, unlike common single 
strain colonisation in high density flocks (Cawthraw & 
Newell, 2010).   
However, modern increased biosecurity practices in 
mass poultry meat production is both removing this 
vaccine option through aiming for Campylobacter-free 
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meat production, and severely curtailing the range of local 
environmental strains encountered. This raises interesting 
ethical dilemmas, if this common food product has such a 
community-wide immune stimulating protective potential, 
then deliberately introducing practices, such as free-range 
farming, in order that a wide range of local environmental 
strains of Campylobacter are present at slaughter makes 
sense. However, this could also increase the risks of point 
source outbreak and other cross-contamination events 
occurring. 
 
Conclusion 
While it is sometimes difficult to establish a specific 
source, outbreaks of campylobacteriosis are generally 
clear cut and essentially resolve to specific point sources. 
The far higher incidence of sporadic cases is more 
problematic to explain, especially considering the 
difficulties with security of source attribution via poultry 
meat contamination, although there is little doubt this is 
very likely to be a contributing source. However, the 
emphasis on attempting to control poultry as the primary 
source has so far contributed relatively little to reducing 
the incidence of camplyobacteriosis in the long term.  
Advances in understanding of immune responses, not 
only for the development of vaccines in animals, but also 
understanding the otherwise baffling sporadic incidence 
pattern in humans, may contribute far more. In this regard, 
recognising the broad environmental prevalence of 
Campylobacter species via a ‘miasma’ view, and applying 
an immunological lens, may move the debate forward. It 
could return the focus to reducing the incidence of 
campylobacteriosis, by understanding the environmental 
ubiquity of the bacteria and associated ongoing priming of 
our immune system rather than attempting to eliminate 
this organism from food sources that has so far been only 
modestly effective. 
Failure to embrace this concept is more likely to 
entrench the current chicken source only belief concept 
approach which ‘is a riddle, wrapped in a mystery, inside 
an enigma’ (Churchill, 1939); but perhaps there is a key, 
in this framework of a ‘miasma’-induced immunity. 
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